Hao, Meng; Luque-Fernandez, Miguel Angel; Lopez, Diana; Cote, Kathryn; Newfield, Jessica; Connors, Molly; Vaidya, Anand; (2019) Benign Adrenocortical Tumors and the Detection of Nonadrenal Neoplasia. International journal of endocrinology, 2019. 9035407-. ISSN 1687-8337 DOI: https://doi.org/10.1155/2019/9035407

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655442/

DOI: https://doi.org/10.1155/2019/9035407

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Context. Patients with adrenocortical tumors have been frequently observed to have nonadrenal neoplasia. Objective. To investigate whether patients with benign adrenocortical tumors have a higher likelihood of having nonadrenal neoplasia detected. Design and Participants. Case-control study of patients with benign adrenocortical tumors (cases; n = 400) and normal adrenal glands (controls; n = 400), who underwent repeated abdominal cross-sectional imaging. Main Outcomes. Primary analyses: association between case-control status and benign abdominal neoplasm detected via cross-sectional imaging. Secondary analyses: association between case-control status and tumors detected via other imaging modalities. Results. The mean interval of abdominal imaging was 4.7 (SD = 3.8) years for cases and 5.9 (4.8) years for controls. Cases were more likely to have detected intraductal papillary mucinous neoplasms (IPMNs) of the pancreas (8.5% vs. 4.5%, adjusted OR = 2.22, 95% CI (1.11, 4.63)) compared with controls. In secondary analyses, cases were more likely to have detected thyroid nodules (25.5% vs. 17.0%, adjusted OR = 1.77, 95% CI (1.15, 2.74)), hyperparathyroidism or parathyroid adenomas (3.5% vs. 1.3%, adjusted OR = 3.00, 95% CI (1.00, 11.64)), benign breast masses (6.0% vs. 3.3%, adjusted OR = 3.25, 95% CI (1.28, 8.78)), and benign prostatic hyperplasia (20.5% vs. 5.3%, adjusted OR = 3.20, 95% CI (1.14, 10.60)). Using a composite outcome, cases had higher odds of detection of the composite of IPMN, thyroid nodules, parathyroid tumors, benign breast masses, and prostate hyperplasia compared with patients with normal adrenal glands. These associations may have important implications for patient care and healthcare economics, regardless of whether they reflect incidental discoveries due to imaging detection or frequency bias, or a common risk for developing multiple neoplasia.

1. Introduction

Benign adrenocortical tumors are common incidental findings on abdominal computed tomography (CT) and magnetic resonance imaging (MRI) scans [1]. As imaging technologies are increasingly used in clinical evaluations, these incidental findings are becoming more prevalent. While most adrenocortical tumors are benign and presumed to be the consequence of somatic alterations, there are rare instances when they are driven by heritable genetic alterations. For instance, adrenocortical tumors are well-known manifestations of rare and classical genetic tumor syndromes such as Li-Fraumeni, Beckwith–Wiedemann, multiple endocrine neoplasia type 1, familial adenomatous polyposis, and Carney complex and are seen with newer inheritable mutations. These classical tumor syndromes are
associated with varying morphologies of adrenocortical neoplasia including hyperplasia, adenomas, and carcinomas, thus linking the development of adrenal neoplasia with a variety of extra-adrenal neoplasms via inherited mechanisms.

While the exact cause and risk factors for the high incidence of adrenocortical tumors are not fully resolved, genetic susceptibilities or common environmental exposures may increase the overall risk of neoplasia in multiple organs. For example, previous research on intraductal papillary mucinous neoplasms (IPMNs) has shown that patients with IPMNs have a higher risk for concomitant extrapancreatic neoplasms in the absence of any syndromic diagnosis [2–4]. Similarly, patients with adrenal incidentalomas have been observed to have a higher prevalence of thyroid nodules [5], and patients with pituitary adenomas may be at a higher risk for developing primary tumors at other sites [6–11]. Data from the nationwide Swedish Family-Cancer Database which examined the risk of subsequent primary neoplasms after the occurrence of an endocrine gland tumor [12] found that the risk for a second endocrine tumor was substantially higher following the first [12]; thereby, suggesting that the development of a benign endocrine tumor may increase the likelihood of developing subsequent tumors [12].

Herein, we sought to systematically investigate whether patients with an adrenocortical tumor, but without any known syndromic or inherited diagnosis, were more likely to have detected other benign abdominal or extra-abdominal neoplasia. We conducted a case-control study among patients who underwent repeated abdominal cross-sectional imaging over time to assess whether having a benign adrenocortical tumor was associated with a higher risk of detection of other benign abdominal, and extra-abdominal, neoplasia when compared with patients with normal adrenal glands.

2. Methods

2.1. Study Population. We designed a traditional case-control study with a cumulative sampling design. Cases and controls were both drawn from a single institutional research registry of all patients from Brigham and Women’s Hospital, Massachusetts General Hospital, and their affiliated partner hospitals (Figure 1). We searched this registry for any patient with abdominal CT or MRI assessments from 1989 to 2016 (n = 234, 267) and excluded patients with known or possible adrenal malignancy or adrenal hormonal diagnosis such as primary aldosteronism, Cushing’s syndrome, congenital adrenal hyperplasia, and pheochromocytoma. Cases were selected from those with diagnosis codes for benign adrenocortical tumor (n = 1,346), while three times as many controls were selected from those with no adrenal tumor (n = 4,041). We completely reviewed medical records from an arbitrary sample of 481 consecutive cases and 513 controls, with no efforts to match or pair selections, and excluded patients with insufficient information (lack of documentation of comprehensive clinical evaluations) or if they were < 18 years old. Comprehensive clinical evaluations included any annual physical examination, primary care or general internal medicine visits, medical subspecialty consultations, and preoperative anesthesia consultations. We also attempted to exclude anyone with a diagnosis of any known genetic syndrome associated with adrenocortical adenoma, including multiple endocrine neoplasia type 1, Li-Fraumeni, McCune Albright syndrome, Carney complex, Beckwith-Wiedemann syndrome, familial adenomatous polyposis, and congenital adrenal hyperplasia; however, after careful review of medical records, no participant had documentation of such diagnoses. We reviewed each patient’s radiology reports and considered cases as having a benign adrenocortical tumor if the tumor had a lipid-rich attenuation (<10 Hounsfield Units) on unenhanced CT imaging, high contrast washout on CT imaging (if available), a marked drop in signal intensity on MRI imaging suggestive of a lipid-rich adenoma, and/or other descriptors that are suggestive of a benign tumor, such as “benign” or “adenoma” or “myelolipoma.” We excluded any potential cases with an adenral abnormality not consistent with a benign adrenocortical tumor (potential malignancy, cyst, hemorrhage, and other nonbenign entity) and any potential controls with evidence of an adrenal abnormality (adenoma, thickening, metastatic disease, cyst, and hemorrhage) for a final study population of 400 cases with benign adrenocortical tumors and 400 controls with no evidence of any adrenal abnormality.

2.2. Assessment of Baseline Characteristics. We collected demographic information (age, sex, race, weight, height, and derived body mass index (BMI) in kg/m²), smoking status, and hospital affiliation of primary care providers from each patient’s electronic medical record. We then determined the first abdominal imaging study that demonstrated benign adrenocortical tumor or normal adrenal glands for cases and controls, respectively. This was considered the baseline timepoint for adrenal morphology assessment. We collected data on cardiovascular comorbidities (hypertension, hyperlipidemia, coronary artery disease, myocardial infarction, and prediabetes or type 2 diabetes mellitus) and medications from baseline. Hyperlipidemia was defined as a documented diagnosis and/or a low-density lipoprotein cholesterol level of ≥150 mg/dL (3.89 mmol/L). Composite diabetes was defined as having either a documented diagnosis of prediabetes or type 2 diabetes mellitus. Any patient with ≥2 documented hemoglobin A1c value of 5.7% to 6.4% (no hypoglycemic agent other than metformin) was considered to have prediabetes, and any patient with ≥2 documented hemoglobin A1c value ≥ 6.5% was considered to have type 2 diabetes mellitus. We identified the most recent abdominal CT/MRI for all patients and calculated the interval of imaging follow-up defined by the time elapsed from the initial to the most recent abdominal imaging study. The interval of imaging follow-up was used as a proxy of the opportunity to detect the presence of extra-adrenal abdominal neoplasia over time.

2.3. Primary Outcome Assessment: Abdominal Neoplasia Detected via Abdominal CT/MRI. We individually reviewed each patient’s entire collection of abdominal CT or MRI reports in the interval of imaging follow-up for benign
tumors of the major abdominal organs assessed including the hepatobiliary system, pancreas, spleen, and kidneys (Table 1). Since all included participants had repeated abdominal cross-sectional imaging studies over time, the opportunity to detect these abdominal tumors among cases and controls was similar and the risk for imaging detection bias deemed to be minimal.

2.4. Secondary Outcomes Assessments: Extra-Abdominal Benign and Malignant Tumors. We recorded the detection of other benign neoplasia of extra-abdominal organs from all other available imaging modalities and the colon from colonoscopy reports (Table 2). We also reviewed each patient’s medical records for any clinical diagnoses of malignant tumors or cancer based on physician/provider documentation, reference to pathology reports, or ICD coding. The use of other imaging modalities besides abdominal CT/MRI was not standardized, and the number of additional imaging studies could not be reliably quantified using our open electronic medical health records system; therefore, our study design could not confidently differentiate whether extra-abdominal tumor detection was the cause or consequence of imaging selection bias (for example, patients with adrenocortical tumors may undergo more extra-abdominal imaging studies than those without adrenocortical tumors and thereby a greater discovery rate of incidental findings) or true differences in tumor incidence.

2.5. Statistical Analysis. We present patients’ baseline and demographic characteristics by case-control status using frequencies and percentages for categorical variables and means and standard deviations for continuous variables. Univariate differences between baseline and demographic characteristic by case-control status are presented using chi-square, Fisher’s exact, and Student’s t-test tests. The associations between case-control status and individual nonadrenal neoplasia were evaluated by computing univariate odds ratios and their respective 95% confidence intervals (CI) and by fitting multivariate logistic regression models adjusted for age, sex, race, BMI, smoking status, imaging interval duration (defined as the time interval between first and last available abdominal imaging study), and cardiovascular comorbidities (hypertension, hyperlipidemia, composite diabetes, coronary artery disease, and myocardial infarction). When assessing the risk for thyroid nodules, we also conducted sensitivity analysis restricted to only thyroid nodules that were ≥1 cm and thyroid nodules that had cytology confirmation of benign cells. Statistical analyses were performed by using R version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).

3. Results

3.1. Baseline Demographics and Characteristics. Demographic and clinical data of cases and controls are presented in Table 3. Cases were more likely to be male, white, and older in age and have a higher BMI and prevalence of diabetes compared with controls. Both cases and controls had approximately 5 years of abdominal cross-sectional imaging follow-up to examine for abdominal tumors, although...
**Table 1: Outcome assessments on abdominal cross-sectional imaging.**

| Organ/gland | Benign neoplasia | Detection modality |
|-------------|------------------|--------------------|
| Hepatobiliary | Hepatobiliary hemangioma or adenoma  
Hepatic cysts | Abdomen CT/MRI |
| Pancreas | Intraductal pancreatic mucinous neoplasm  
Splenic hemangioma and cysts  
Renal angiomyolipoma  
Renal cysts | |
| Spleen | Spleenic hemangioma and cysts | Abdomen CT/MRI |
| Kidneys | | Abdomen CT/MRI |

**Table 2: Outcome assessments on other imaging modalities.**

| Organ/gland | Benign neoplasia | Detection modality |
|-------------|------------------|--------------------|
| Meninges | Meningioma | Brain MRI |
| Pituitary | Pituitary adenoma | Head CT |
| Thyroid | Thyroid nodule | Thyroid ultrasound  
head, neck, or chest CT  
Parathyroid scan with SPECT CT  
Parathyroidectomy and pathology  
PTH labs and clinical diagnosis | |
| Parathyroid | Hyperparathyroidism or  
Parathyroid adenoma  
Fibroadenoma | Breast biopsy pathology  
Surgical excision pathology | |
| Breasts | Papilloma  
Other benign neoplasm  
Breast cysts | Colon adenoma  
Benign prostatic hyperplasia  
Lipoma  
Endometrial polyp  
Cervical polyp  
Ovarian cyst | Colonoscopy  
Clinical diagnosis  
Pelvic CT/MRI  
Clinical diagnosis  
CT/MRI  
Pelvic CT/MRI  
Pelvic ultrasound | |

**Table 3: Baseline demographic and clinical characteristics of cases and controls.**

| Characteristic | Cases (adrenocortical tumor) | Controls (normal adrenal) | P value |
|----------------|-------------------------------|---------------------------|---------|
| Patients, n   | 400                           | 400                       |         |
| Mean age, years (SD) | 62.7 (12.9)  
58.3 (14.5) | | <0.001 |
| Sex           |                               |                           |         |
| Female        | 268 (67.0%)  
306 (76.5%) | 216 (54.0%)  
257 (64.3%) | 0.001 |
| Male          | 132 (33.0%)  
94 (23.5%)  | | |
| Race          |                               |                           |         |
| White         | 294 (73.5%)  
257 (64.3%) | 173 (43.3%)  
216 (54.0%) | 0.043 |
| Black         | 29 (7.25%)   
37 (9.3%) | 227 (56.7%)  
184 (46.0%) | 0.37 |
| Hispanic      | 16 (4.0%)    
26 (6.5%) | | |
| Others        | 61 (15.25%)  
80 (20.0%) | 237 (59.3%)  
251 (62.8%) | 0.31 |
| Institutional primary care provider | 237 (59.3%)  
251 (62.8%) | 251 (62.8%)  
251 (62.8%) | 0.31 |
| Mean BMI, kg/m² (SD) | 29.5 (6.9)  
28.5 (7.0) | 29.5 (6.9)  
28.5 (7.0) | 0.047 |
| Interval of abdominal cross-sectional imaging*, years (SD) | 4.7 (3.8)  
5.9 (4.8) | 4.7 (3.8)  
5.9 (4.8) | 0.007 |
| Smoking status |                               |                           |         |
| Nonsmoker     | 173 (43.3%)  
216 (54.0%) | | 0.37 |
| Current or past smoker | 227 (56.7%)  
184 (46.0%) | | |
| Comorbidity   |                               |                           |         |
| Hypertension  | 242 (60.5%)  
193 (48.2%) | | 0.41 |
| Diabetes or prediabetes | 107 (26.7%)  
71 (17.8%) | 107 (26.7%)  
71 (17.8%) | 0.04 |
| Hyperlipidemia | 207 (51.7%)  
169 (42.2%) | | 0.92 |
| Coronary artery disease | 60 (15.0%)  
40 (10.0%) | | 0.62 |
| Myocardial infarction | 29 (7.2%)  
16 (4.0%) | | 0.50 |

**Note.** *Interval of imaging defined as the time period between the initial and most recent cross-sectional abdominal imaging study.*
cases had a slightly shorter opportunity to detect tumors (Table 3).

3.2. Primary Outcome: Benign Abdominal Neoplasia Detected via Abdominal CT/MRI. The adjusted odds ratios for each benign nonadrenal tumor type detected via abdominal cross-sectional imaging are presented in Table 4. Cases had significantly higher odds of having a pancreatic IPMN (adjusted OR = 2.22, 95%CI: 1.11, 4.63). There were non-significant trends, further limited by small sample sizes, suggesting that cases may be more likely to have hepatic cysts, splenic hemangioma or cysts, renal angiomyolipoma, and renal cysts when compared with controls.

3.3. Secondary Outcomes Assessments: Extra-Abdominal Benign and Malignant Tumors. The adjusted odds ratios for each extra-abdominal tumor type detected via other modalities are presented in Table 5. Cases had significantly higher odds of having a thyroid nodule (adjusted OR = 1.77, 95%CI: 1.15, 2.74), parathyroid tumors and hyperparathyroidism (adjusted OR = 3.00, 95%CI: 1.00, 11.64), benign breast tumors (adjusted OR = 3.25, 95%CI: 1.28, 8.78), and benign prostatic hyperplasia (adjusted OR = 3.20, 95%CI: 1.14, 10.60). In sensitivity analyses restricted to only thyroid nodules that were ≥1 cm and thyroid nodules that had cytology confirmation of benign cells, cases still had higher odds of having thyroid nodules compared with controls, although the sample size was much smaller and confidence intervals crossed 1.00 (adjusted OR = 1.72, 95%CI: 0.73, 4.13 and adjusted OR = 2.12, 95%CI: 0.87, 5.50, respectively). There were no differences in the risk for any malignant tumors or cancer (Table 6).

3.4. Composite Outcome. When using a composite outcome for extra-adrenal neoplasia, having a benign adrenocortical tumor (case status) was associated with significantly higher odds of detection of the composite of IPMN, thyroid nodules, parathyroid tumors, benign breast masses, and prostate hyperplasia (adjusted OR = 2.36, 95%CI: 1.60, 3.50) when compared to patients with normal adrenal glands (control status).

4. Discussion

It is common for adrenocortical tumors to be detected serendipitously with abdominal imaging performed for other reasons. While most of these tumors are benign and sporadic, adrenocortical tumors are also phenotypic manifestations of certain classical inherited tumor syndromes. The observations of our current study suggest that even in the absence of known syndromic neoplasia, patients with benign-appearing adrenocortical tumors may be more likely to have detected IPMNs, as well as benign neoplasia of the thyroid, parathyroid, breast, and prostate. Whether these tumors of different organs were incidentally detected due to imaging performance bias or imaging detection bias, or are causally linked through a common pathway, could not be assessed with the current study design; however, the ultimate observation has important implications for the clinical care of patients, regardless of the reason for the detection difference. The possibility that patients with an incidentally detected adrenocortical tumor are more likely to have detected extra-adrenal tumors (either due to excessive scrutiny of available images or via additional imaging studies ordered) could have major implications for healthcare spending and patient care. Alternatively, the possibility that there is a casual link between adrenocortical tumors and these extra-adrenal tumors, as discussed below, may also have important implications, given how common adrenocortical tumors are.

The association between having adrenocortical tumors and IPMNs was robust and independent of numerous potential confounders. Both cases and controls underwent repeated cross-sectional abdominal imaging over time wherein controls were imaged over a longer interval of time, thereby providing greater opportunity to detect potential tumors. In this regard, the observation that IPMNs are more likely to be detected among cases (patients with adrenocortical tumors) is unlikely to be due to detection or imaging bias. In this regard, our findings support prior studies demonstrating that having one endocrine neoplasm may increase the risk of having other tumors [12] and that having an IPMN is associated with having other nonpancreatic tumors [2–4]. In contrast, our secondary observations that adrenocortical tumors were also associated with a higher likelihood of having benign tumors of the thyroid, parathyroid, breast, and prostate were less robust. The study was designed with standardized abdominal cross-sectional imaging between cases and controls, and therefore, the confidence and consistency in the detection of abdominal tumors was high. However, the study design could not standardize the indications or frequency/number of imaging studies focused on the neck, chest, pelvis, and other sites. Since we could not reliably account for these factors, it is possible that the association of having tumors of the thyroid, parathyroid, breast, and prostate among individuals with adrenocortical tumors may be due to imaging performance and/or detection bias, wherein patients with adrenocortical tumors could have undergone more imaging studies with closer scrutiny for other tumors, rather than a true causal link.

Regardless of the mechanistic explanation for the association, these observations highlight an important clinical phenomenon: patients with adrenocortical tumors are either more likely to have detected, or more likely to develop, benign neoplasia of the pancreas, thyroid, parathyroid, breast, and/or prostate. It may certainly be possible that the incidental detection of one tumor, directly or indirectly, leads to more imaging procedures that result in the detection of other incidental tumors (a factor our study design could not reliably quantify). Whether this is of benefit to patients (i.e., early detection of potentially harmful processes) or a burden to patients and healthcare spending (i.e., excessive detection of benign and clinically innocuous tumors) is an important query for the medical field to consider. Future work should therefore focus on elucidating whether the
Table 4: Risk for benign abdominal neoplasia detected via abdominal cross-sectional imaging.

| Benign abdominal neoplasm                  | Cases (adrenocortical tumor) | Controls (normal adrenal) | OR (95% CI) | AOR (95% CI)* |
|-------------------------------------------|------------------------------|---------------------------|-------------|---------------|
| n                                        | 400                          | 400                       |             |               |
| Hepatobiliary hemangioma or adenoma       | 26 (6.5%)                    | 19 (4.8%)                 | 1.39 (0.76, 2.59) | 1.30 (0.61, 2.79) |
| Hepatic cyst                              | 109 (27.3%)                  | 91 (22.8%)                | 1.27 (0.93, 1.75) | 1.44 (0.98, 2.17) |
| Intraductal pancreatic mucinous neoplasm  | 34 (8.5%)                    | 18 (4.5%)                 | 1.97 (1.11, 3.62) | 2.22 (1.11, 4.63) |
| Splenic hemangioma and cyst               | 16 (4.0%)                    | 10 (2.5%)                 | 1.62 (0.74, 3.75) | 4.46 (0.92, 7.01) |
| Renal angiomyolipoma                      | 9 (2.3%)                     | 4 (1.0%)                  | 2.28 (0.73, 8.46) | 4.50 (0.94, 33.10) |
| Renal cyst                                | 216 (54.0%)                  | 167 (41.8%)               | 1.64 (1.24, 2.16) | 1.25 (0.86, 1.81) |

Note. The unadjusted and adjusted* odds ratio for patients with benign adrenocortical tumors (cases) compared with those with normal adrenal glands (controls) are presented along with 95% confidence intervals for each benign abdominal neoplasm. AOR: adjusted odds ratio; *adjusted for age, sex, race, smoking status, BMI, duration imaging interval, hypertension, hyperlipidemia, composite diabetes (diabetes or prediabetes), coronary artery disease, and myocardial infarction.

Table 5: Risk for benign neoplasia detected via other modalities.

| Other benign neoplasm                  | Cases (adrenocortical tumor) | Controls (normal adrenal) | OR (95% CI) | AOR (95% CI)* |
|----------------------------------------|------------------------------|---------------------------|-------------|---------------|
| n                                      | 400                          | 400                       |             |               |
| Meningioma                             | 11 (2.8%)                    | 5 (1.3%)                  | 2.23 (0.80, 7.14) | 2.45 (0.61, 12.42) |
| Pituitary adenoma                      | 24 (9.0%)                    | 10 (3.3%)                 | 0.49 (0.29, 0.81) | 0.59 (0.31, 1.10) |
| Thyroid nodule                         | 102 (25.5%)                  | 68 (17.0%)                | 1.67 (1.19, 2.36) | 1.77 (1.15, 2.74) |
| Thyroid nodule ≥ 10 mm                 | 66 (16.5%)                   | 35 (8.8%)                 | 1.88 (0.98, 3.63) | 1.72 (0.73, 4.13) |
| FNA benign thyroid                     | 35 (8.8%)                    | 17 (4.3%)                 | 1.62 (0.82, 3.29) | 2.12 (0.87, 5.50) |
| Hyperparathyroidism or parathyroid adenoma | 14 (3.5%)                  | 5 (1.3%)                  | 2.87 (1.08, 9.03) | 3.00 (1.00, 11.64) |
| Benign breast Mass                     | 16 (6.0%)                    | 10 (3.3%)                 | 1.62 (0.73, 3.75) | 3.25 (1.28, 8.78) |
| Breast cyst                            | 24 (9.0%)                    | 46 (15.0%)                | 0.49 (0.29, 0.81) | 0.59 (0.31, 1.10) |
| Colon adenoma                          | 164 (41.0%)                  | 136 (34.0%)               | 1.34 (1.01, 1.79) | 1.15 (0.80, 1.65) |
| Benign prostatic hyperplasia           | 27 (20.5%)                   | 5 (3.3%)                  | 5.71 (2.37, 17.00) | 3.20 (1.14, 10.60) |
| Lipoma                                  | 53 (13.3%)                   | 46 (11.5%)                | 1.14 (0.77, 1.79) | 1.08 (0.63, 1.68) |
| Fibroid                                | 86 (32.1%)                   | 95 (31.0%)                | 0.88 (0.63, 1.22) | 1.36 (0.89, 2.12) |
| Endometrial polyp                      | 25 (9.3%)                    | 35 (11.4%)                | 0.89 (0.40, 1.79) | 0.78 (040, 1.49) |
| Cervical polyp                         | 22 (8.2%)                    | 31 (10.1%)                | 0.69 (0.39, 1.21) | 0.92 (0.46, 1.82) |
| Ovarian cyst                           | 54 (20.1%)                   | 83 (27.1%)                | 0.60 (0.41, 0.86) | 1.40 (0.85, 2.34) |

Note. The unadjusted and adjusted* odds ratio for patients with benign adrenocortical tumors (cases) compared with those with normal adrenal glands (controls) are presented along with 95% confidence intervals for each benign neoplasm. AOR: adjusted odds ratio; *adjusted for age, sex, race, smoking status, BMI, duration imaging interval, hypertension, hyperlipidemia, composite diabetes (diabetes or prediabetes), coronary artery disease, and myocardial infarction.

Table 6: Risk for malignant tumors.

| Malignancy                        | Cases (adrenocortical tumor) | Controls (normal adrenal) | OR (95% CI) | AOR (95% CI)* |
|-----------------------------------|------------------------------|---------------------------|-------------|---------------|
| Gastrointestinal cancer           | 22 (5.5%)                    | 29 (7.3%)                 | 0.74 (0.42, 1.32) | 0.84 (0.42, 1.69) |
| Renal/bladder cancer              | 14 (3.5%)                    | 18 (4.5%)                 | 0.77 (0.38, 1.57) | 0.98 (0.41, 2.33) |
| Breast cancer                     | 36 (9.0%)                    | 50 (12.5%)                | 0.69 (0.44, 1.08) | 0.83 (0.47, 1.46) |
| Lung cancer                       | 23 (5.8%)                    | 12 (3.0%)                 | 2.0 (0.97, 4.02) | 1.73 (0.77, 4.10) |
| Brain cancer                      | 2 (0.5%)                     | 4 (1.0%)                  | 0.45 (0.09, 2.73) | NA |
| Endocrine cancer                  | 13 (3.3%)                    | 11 (2.8%)                 | 1.28 (0.53, 2.68) | 1.53 (0.60, 4.11) |
| Hematologic cancer                | 15 (3.8%)                    | 24 (6.0%)                 | 0.61 (0.31, 1.18) | 0.59 (0.27, 1.25) |
| Melanoma/sarcoma                  | 4 (1.0%)                     | 14 (3.5%)                 | 0.28 (0.09, 0.85) | 0.19 (0.05, 0.59) |
| Gynecologic cancer                | 15 (3.7%)                    | 20 (5.0%)                 | 0.74 (0.37, 1.47) | 0.57 (0.24, 1.26) |
| Prostate/testicular cancer         | 13 (3.2%)                    | 16 (4%)                   | 0.80 (0.38, 1.70) | 0.49 (0.16, 1.50) |
| Other cancer                      | 3 (0.8%)                     | 2 (0.5%)                  | 1.50 (0.25, 9.04) | NA |

Note. The unadjusted and adjusted* odds ratio for patients with benign adrenocortical tumors (cases) compared with those with normal adrenal glands (controls) are presented along with 95% confidence intervals for each malignancy. AOR: adjusted odds ratio; *adjusted for age, sex, race, smoking status, BMI, duration imaging interval, hypertension, hyperlipidemia, composite diabetes (diabetes or prediabetes), coronary artery disease, and myocardial infarction.
associations between high BMI and diabetes with increased insulin, insulin-like growth factors, and sex steroids and may promote tumorigenesis through increased levels of glucocorticoids. Studies have also suggested that high BMI and adiposity result in greater suppression of apoptosis [22–27].

Our study must be interpreted within the context of our study design. Bias is an important consideration in case-control studies. We attempted to limit selection bias by using arbitrary selection of consecutive patients from the same institutional database. Differences in the imaging frequency of abdominal and extra-abdominal organs represent another source of bias, as discussed extensively above. The frequency of abdominal imaging was not standardized; however, the use of cross-sectional abdominal imaging was required, and the imaging interval over time permitted ample opportunity to detect abdominal tumors in both cases and controls. In fact, we observed that even though patients with normal adrenal glands (controls) were imaged over a longer interval of time, patients with adrenal tumors (cases) had significantly higher odds of having abdominal pancreatic IPMNs. We also observed nonsignificant trends suggesting a higher risk for several other benign tumors and masses; larger sample sizes would be needed to ascertain whether these trends are suggestive of true associations. Given the observational and retrospective nature of this study, the indications for various types of diagnostic imaging in our secondary analyses were not controlled, and it is possible that cases were subjected to more imaging opportunities than controls. We could not confidently quantify the number of imaging tests each patient underwent since patients may have undergone some testing outside of our health system; however, even if cases underwent more frequent imaging, the interpretations of our findings still implicate that patients with adrenocortical tumors have a higher likelihood of detection of benign extra-adrenal neoplasia. Our study was not designed to determine the directionality or temporal relationship between development of adrenal neoplasia and extra-adrenal neoplasia, or the involvement of another factor (genetic or environmental). Therefore, we cannot make firm conclusions regarding the direction, timing, or pathogenic cause of these findings. Because our observations were based on standard clinical care, patients did not undergo repeated evaluations for subclinical hypercortisolism, or other adrenal hormone excess, which can contribute to cardiometabolic diseases. In addition, while patients in our study did not have clinical diagnoses to indicate known genetic tumor syndromes, we did not have the ability to conduct systematic genetic testing to confirm this, nor evaluate potential genetic contributions to our findings. Lastly, while we adjusted for all potential covariates available to us, there remains a risk for residual confounding.

In conclusion, we observed that having benign adrenocortical neoplasia was associated with a significantly higher likelihood of detection of pancreatic IPMN and other benign neoplasia or hyperplasia of the thyroid, parathyroid, breast, and prostate, in the absence of a diagnosis of a known genetic tumor syndrome. It is possible that these findings are
the result of detection or imaging bias resulting in increased frequency of incidental tumor detection, mild or common pathogenic variants of rare genetic syndromes in the population, and/or unrecognized environmental exposures. Regardless of the underlying cause of this observation, these findings have important implications in determining the oncologic risk profile and clinical management of patients found to have adrenocortical adenomas.

**Data Availability**

Deidentified data supporting the conclusions of the study can be requested from the corresponding author by investigators with local institutional research ethics approval.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Acknowledgments**

The authors thank their funding sources. Meng Hao was supported by the Endocrine Society Summer Research Fellowship, by Scholars in Medicine at Harvard Medical School. Dr. Anand Vaidya was supported by the National Fellowship, by Scholars in Medicine at Harvard Medical School. Dr. Anand Vaidya was supported by the National Institutes of Health under awards R01 DK107407 and R01 DK115392. Miguel Angel Luque was supported by the Endocrine Society Summer Research Fellowship, by Scholars in Medicine at Harvard Medical School. Dr. Anand Vaidya was supported by the National Institutes of Health under awards R01 DK107407 and R01 DK115392. Miguel Angel Luque was supported by the National Institutes of Health under awards R01 DK107407 and R01 DK115392. Miguel Angel Luque was supported by the National Institutes of Health under awards R01 DK107407 and R01 DK115392. Miguel Angel Luque was supported by the National Institutes of Health under awards R01 DK107407 and R01 DK115392.

**References**

[1] M. Fassnacht, W. Arlt, I. Bancos et al., “Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors,” European Journal of Endocrinology, vol. 175, no. 2, pp. G1–G34, 2016.

[2] M.-G. Choi, S.-W. Kim, S.-S. Han, J. Y. Jang, and Y.-H. Park, “High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms,” Archives of Surgery, vol. 141, no. 1, pp. 51–56, 2006.

[3] K. M. Reid-Lombardo, K. L. Mathis, C. M. Wood, W. S. Harmsen, and M. G. Sarr, “Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management,” Annals of Surgery, vol. 251, no. 1, pp. 64–69, 2010.

[4] M. Sugiyama and Y. Atomi, “Extrapancreatic neoplasms occur with unusual frequency in patients with intraductal papillary mucinous tumours of the pancreas,” American Journal of Gastroenterology, vol. 94, no. 2, pp. 470–473, 1999.

[5] A. Arduc, S. Isik, U. Onguz et al., “Relationship between thyroid nodules and non-functioning adrenal incidentalomas and their association with insulin resistance,” Endocrine Research, vol. 39, no. 3, pp. 99–104, 2013.

[6] W. T. Couldwell and L. A. Cannon-Albright, “Co-prevalence of other tumors in patients harboring pituitary tumors,” Journal of Neurosurgery, vol. 121, no. 6, pp. 1474–1477, 2014.

[7] T. N. Niazi, L. A. Cannon-Albright, and W. T. Couldwell, “Utah population database: a tool to study the hereditary element of nonsyndromic neurosurgical diseases,” Neurosurgical Focus, vol. 28, no. 1, p. E1, 2010.

[8] J. Dénes, F. Swords, E. Rattenberry et al., “Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 3, pp. E531–E541, 2015.

[9] S. Furtado, P. Venkatesh, N. Ghosal, and A. Hegde, “Coexisting intracranial tumors with pituitary adenomas: genetic association or coincidence?,” Journal of Cancer Research and Therapeutics, vol. 6, no. 2, pp. 221–223, 2010.

[10] A. Wajngot, S. Werner, P. O. Granberg, and N. Lindvall, “Occurrence of pituitary adenomas and other neoplastic diseases in primary hyperparathyroidism,” Surgery, Gynecology & Obstetrics, vol. 151, no. 3, pp. 401–403, 1980.

[11] V. Popovic, S. Damjanovic, D. Micic et al., “Increased incidence of neoplasia in patients with pituitary adenomas,” Clinical Endocrinology, vol. 49, no. 4, pp. 441–445, 1998.

[12] K. Hemminki and Y. Jiang, “Second primary neoplasms after 19281 endocrine gland tumours,” European Journal of Cancer, vol. 37, no. 15, pp. 1886–1894, 2001.

[13] F. Tissier, C. Cavard, L. Groussin et al., “Mutations of β-catenin adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors,” Cancer Research, vol. 65, no. 17, pp. 7622–7627, 2005.

[14] S. Bonnet, S. Gaujoux, P. Launay et al., “Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 2, pp. E419–E426, 2011.

[15] S. Gaujoux, F. Tissier, L. Groussin et al., “Wnt/β-catenin and 3’, 5’-cyclic adenosine 5'-monophosphate/protein kinase a signaling pathways alterations and somatic β-catenin gene mutations in the progression of adrenocortical tumors,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 10, pp. 4135–4140, 2008.

[16] R. Chetty, S. Serra, S. Salalshor et al., “Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis,” Human Pathology, vol. 37, no. 2, pp. 212–217, 2006.

[17] P. Björklund, G. Åkerström, and G. Westin, “Accumulation of nonphosphorylated beta-catenin and c-myc in primary and malignant adrenocortical tumors,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 1, pp. 338–344, 2007.

[18] P. Björklund, D. Lindberg, G. Åkerström, and G. Westin, “Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients,” Molecular Cancer, vol. 7, no. 1, p. 53, 2008.

[19] H. C. Whitaker, J. Girling, A. Y. Warren, H. Leung, I. G. Mills, and D. E. Neal, “Alterations in β-catenin expression and localization in prostate cancer,” The Prostate, vol. 68, no. 11, pp. 1196–1205, 2008.

[20] J. Vouillarmet, F. Fernandes-Rosa, J. Graeppi-Dulac et al., “Accumulation of Wnt-β-catenin and Apc localization in prostate cancer,” The Prostate, vol. 68, no. 11, pp. 1196–1205, 2008.

[21] A. Talaei, A. Aminorroaya, D. Taheri, and K. N. Mahdavi, “Carney complex presenting with a unilateral adrenocortical
nodule: a case report,” *Journal of Medical Case Reports*, vol. 8, no. 1, p. 38, 2014.

[22] S. Djioague, A. H. Nwabo Kamdje, L. Vecchio et al., “Insulin resistance and cancer: the role of insulin and IGFs,” *Endocrine-Related Cancer*, vol. 20, no. 1, pp. R1–R17, 2013.

[23] E. E. Calle, C. Rodrigues, K. Walker-Thurmond, and M. J. Thun, “Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults,” *New England Journal of Medicine*, vol. 348, no. 17, pp. 1625–1638, 2003.

[24] A. G. Renehan, J. Frystyk, and A. Flyvbjerg, “Obesity and cancer risk: the role of the insulin-IGF axis,” *Trends in Endocrinology & Metabolism*, vol. 17, no. 8, pp. 328–336, 2006.

[25] B. Arcidiacono, S. Iiritano, A. Nocera et al., “Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms,” *Experimental Diabetes Research*, vol. 2012, Article ID 789174, 12 pages, 2012.

[26] E. E. Calle and R. Kaaks, “Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms,” *Nature Reviews Cancer*, vol. 4, no. 8, pp. 579–591, 2004.

[27] A. G. Renehan, M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen, “Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies,” *The Lancet*, vol. 371, no. 9612, pp. 569–578, 2008.

[28] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” *Cell*, vol. 140, no. 6, pp. 883–899, 2010.

[29] R. C. M. van Kruijsdijk, E. van der Wall, and F. L. J. Visseren, “Obesity and cancer: the role of dysfunctional adipose tissue,” *Cancer Epidemiology Biomarkers & Prevention*, vol. 18, no. 10, pp. 2569–2578, 2009.

[30] M. Inoue and S. Tsugane, “Insulin resistance and cancer: epidemiological evidence,” *Endocrine-Related Cancer*, vol. 19, no. 5, pp. F1–F8, 2012.

[31] A. V. Hernandez, V. Pasupuleti, V. A. Benites-Zapata, P. Thota, A. Deshpande, and F. R. Perez-Lopez, “Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis,” *European Journal of Cancer*, vol. 51, no. 18, pp. 2747–2758, 2015.

[32] Q. Ben, M. Xu, X. Ning et al., “Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies,” *European Journal of Cancer*, vol. 47, no. 13, pp. 1928–1937, 2011.

[33] L. Deng, Z. Gui, L. Zhao, J. Wang, and L. Shen, “Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis,” *Digestive Diseases and Sciences*, vol. 57, no. 6, pp. 1576–1585, 2012.